Streetbeat News

Analyst Ratings

HES

Analysts have varied opinions on Hess (NYSE:HES), with recent ratings showing a mix of bullish, indifferent, and bearish sentiments. The average 12-month price target has decreased by 4.94% to $165.0. Hess has shown strong financial performance with significant revenue growth and profitability, but its high debt-to-equity ratio raises concerns.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 1:01 pm

RAPP

Jones Trading has initiated coverage on Rapport Therapeutics with a Buy rating and set a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:01 pm

FTAI

FTAI Aviation (NASDAQ:FTAI) has received 15 analyst ratings in the last three months, with a majority being bullish. Analysts have raised their 12-month price targets, reflecting a positive outlook. Despite strong revenue growth, FTAI faces challenges with profitability and financial performance metrics.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 1:01 pm

CORT

Corcept Therapeutics (NASDAQ:CORT) has received a range of analyst ratings over the past three months, with a majority being bullish. Analysts have raised their 12-month price targets significantly, indicating positive sentiment. The company has shown strong revenue growth and net margins, but its return on equity is below industry standards.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 1:01 pm

SHW

Sherwin-Williams (NYSE:SHW) has been analyzed by 16 analysts, showing a range of perspectives from bullish to bearish. Recent analyst actions include several upgrades in price targets, with an average target of $394.31, marking an 8.44% increase from the previous average. Sherwin-Williams is the largest provider of architectural paint in the US, with strong financial metrics but a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 1:00 pm

ECL

Ecolab (NYSE:ECL) has been analyzed by 13 analysts, showing a range of opinions from bullish to bearish. Recent analyst actions include several upgrades and a few downgrades, with a current average price target of $274.92, up 7.71% from the previous target. Ecolab's financial performance is strong, with a high net margin and effective debt management.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 1:00 pm

APA

Analysts have provided mixed ratings for APA Corporation (NASDAQ:APA) over the past three months, with a decrease in the average 12-month price target from $40.09 to $36.59. Despite positive financial performance, including a 41.59% revenue growth rate and strong profitability metrics, analysts have generally lowered their price targets, reflecting cautious sentiment.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 1:00 pm

AURA

Aura Biosciences shares rose following HC Wainwright & Co.'s decision to maintain a buy rating and increase the price target from $21 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:00 pm

NUE

Nucor Corporation (NYSE:NUE) is set to release its Q3 earnings on Oct. 21, with expected earnings of $1.47 per share, down from $4.57 last year. Revenue is projected at $7.28 billion. JPMorgan has maintained an Overweight rating but lowered the price target to $170. Nucor offers a 1.37% annual dividend yield, translating to $2.16 per share annually. To earn $500 monthly from dividends, an investment of approximately $439,174 is needed.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 12:59 pm

NFLX

Jefferies analyst Andrew Uerkwitz maintains a Buy rating on Netflix and raises the price target from $780 to $800.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:58 pm